A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

(2013) Ali T. Taher et al.   ANNALS OF HEMATOLOGY

Cardiovascular Function and Treatment in β-Thalassemia Major

(2013) Dudley J. Pennell et al.   CIRCULATION

Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection

(2013) Dimitrios Kountouras et al.   LIVER INTERNATIONAL

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

(2012) Elena Cassinerio et al.   ANNALS OF HEMATOLOGY

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy

(2012) J. B. Porter et al.   ANNALS OF HEMATOLOGY

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

Efficacy and safety of deferasirox for reducing total body and cardiac iron in Thalassemia

(2012) Rashid Merchant et al.   INDIAN PEDIATRICS

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

(2011) M. D. Cappellini et al.   BLOOD

Relation of myocardial T2* to right ventricular function in thalassaemia major

(2010) F. Alpendurada et al.   EUROPEAN HEART JOURNAL

Deferasirox (Exjade®) for the Treatment of Iron Overload

(2009) M.D. Cappellini et al.   ACTA HAEMATOLOGICA

History and Current Impact of Cardiac Magnetic Resonance Imaging on the Management of Iron Overload

(2009) John C. Wood   CIRCULATION

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

(2009) Ali Taher et al.   EUROPEAN JOURNAL OF HAEMATOLOGY